Adrenal GRK2 Upregulation Mediates Sympathetic Overdrive in Heart Failure
Overview
Molecular Biology
Affiliations
Cardiac overstimulation by the sympathetic nervous system (SNS) is a salient characteristic of heart failure, reflected by elevated circulating levels of catecholamines. The success of beta-adrenergic receptor (betaAR) antagonists in heart failure argues for SNS hyperactivity being pathogenic; however, sympatholytic agents targeting alpha2AR-mediated catecholamine inhibition have been unsuccessful. By investigating adrenal adrenergic receptor signaling in heart failure models, we found molecular mechanisms to explain the failure of sympatholytic agents and discovered a new strategy to lower SNS activity. During heart failure, there is substantial alpha2AR dysregulation in the adrenal gland, triggered by increased expression and activity of G protein-coupled receptor kinase 2 (GRK2). Adrenal gland-specific GRK2 inhibition reversed alpha2AR dysregulation in heart failure, resulting in lowered plasma catecholamine levels, improved cardiac betaAR signaling and function, and increased sympatholytic efficacy of a alpha2AR agonist. This is the first demonstration, to our knowledge, of a molecular mechanism for SNS hyperactivity in heart failure, and our study identifies adrenal GRK2 activity as a new sympatholytic target.
Canonical or non-canonical, all aspects of G protein-coupled receptor kinase 2 in heart failure.
Kaplan A, El-Samadi L, Zahreddine R, Amin G, Booz G, Zouein F Acta Physiol (Oxf). 2025; 241(3):e70010.
PMID: 39960030 PMC: 11831727. DOI: 10.1111/apha.70010.
Stoicovy R, Cora N, Perez A, Nagliya D, Del Calvo G, Lopez T Inflamm Res. 2024; 73(11):2043-2056.
PMID: 39305297 DOI: 10.1007/s00011-024-01950-0.
Lymperopoulos A, Borges J, Stoicovy R Pharmaceutics. 2024; 16(6).
PMID: 38931817 PMC: 11206770. DOI: 10.3390/pharmaceutics16060693.
Nagliya D, Lopez T, Del Calvo G, Stoicovy R, Borges J, Suster M Int J Mol Sci. 2024; 25(10).
PMID: 38791266 PMC: 11120680. DOI: 10.3390/ijms25105227.
Del Calvo G, Pollard C, Lopez T, Borges J, Suster M, Lymperopoulos A Drug Des Devel Ther. 2024; 18:71-80.
PMID: 38229917 PMC: 10790636. DOI: 10.2147/DDDT.S432453.